Standard BioTools Inc. LAB
0.74
0.00
0.00%
as of 25 Sep
- Market cap
- $291.7M
- P/E
- 3.4×
Follow LAB
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
3.73 | 4.60 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.79 | 4.14 | 5.72 | 7.97 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(31.09) | (7.66) | (410.49) | (22.40) | |
P/B ratio |
0.59 | 0.64 | 1.15 | 1.24 | |
Price to Tangible BV |
0.80 | 0.85 | 1.72 | 1.91 | |
EV/Sales |
(1.78) | (1.08) | 3.59 | 4.93 | |
EV/EBITDA |
1.62 | 1.03 | 0.00 | 0.00 | |
EV/Operating CF |
1.88 | 1.02 | (4.12) | (3.53) | |
EV/FCF |
1.69 | 0.92 | (3.43) | (2.93) | |
Quick Ratio |
8.67 | 11.77 | 1.86 | 1.93 | |
Current Ratio |
9.10 | 12.36 | 4.19 | 4.38 | |
Net Debt/EBITDA |
18.81 | 38.81 | 7.86 | 6.08 | |
Debt/Assets |
0.05% | 0.05% | 0.05% | 0.06% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.14 | 0.14 | 0.10 | |
Operating CF/Net income |
0.39 | (0.37) | (0.06) | 0.64 | |
Capex/Depreciation |
(5.21) | (0.73) | (0.57) | (0.97) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.83% | 10.01% | 33.49% | 32.51% | |
Selling, General and Administrative Expense of Revenue |
81.52% | 87.99% | 106.48% | 136.02% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
20.15% | 41.73% | 24.14% | 43.34% | |
Graham Net Nets |
1.34 | 1.24 | 0.64 | 0.67 | |
Graham Number |
2.62 | 2.55 | 0.00 | 0.00 | |
Earnings Yield |
26.83% | 21.74% | (15.63%) | (26.15%) | |
Free Cash Flow Yield |
(27.82%) | (28.30%) | (18.27%) | (21.11%) | |
Revenue per Share |
0.05 | 0.05 | 0.06 | 0.05 | |
Operating CF per Share |
(0.03) | (0.12) | 0.00 | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.03) | (0.12) | 0.00 | (0.06) | |
Cash per Share |
1.22 | 1.17 | 0.49 | 0.51 | |
Shareholders Equity per Share |
1.38 | 1.45 | 1.11 | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.38 | 1.45 | 1.11 | 1.04 | |
Free Cash Flow |
(10.65) | (47.17) | (1.67) | (23.09) | |
Working Capital |
460.07 | 479.25 | 345.96 | 364.47 | |
Capital Expenditures |
(0.34) | (0.57) | (0.48) | (0.89) | |
Net Current Asset Value |
429.62 | 443.46 | 310.80 | 332.46 | |
EV/EBIT |
1.58 | 0.97 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.05 | |
Net Profit Margin |
(133.10%) | 600.91% | 81.04% | (177.41%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.18 | 38.56 | 14.09 | 24.43 | |
Average Payables |
8.44 | 9.89 | 5.23 | 8.77 | |
Average Inventory |
20.64 | 30.36 | 20.36 | 34.03 | |
Average Assets |
592.09 | 609.36 | 590.05 | 610.59 | |
Average Common Equity |
482.25 | 507.86 | 448.01 | 444.50 |
Columns are period end dates